CINECA IRIS Institutional Research Information System

BOCCI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.452
EU - Europa 5.872
AS - Asia 3.377
AF - Africa 250
SA - Sud America 37
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 28.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.067
IT - Italia 2.111
CN - Cina 1.849
SE - Svezia 1.060
DE - Germania 677
BG - Bulgaria 638
SG - Singapore 604
TR - Turchia 390
CA - Canada 375
GB - Regno Unito 303
VN - Vietnam 286
FI - Finlandia 241
UA - Ucraina 237
CI - Costa d'Avorio 160
RU - Federazione Russa 128
FR - Francia 104
HK - Hong Kong 90
CH - Svizzera 89
IN - India 85
AT - Austria 76
BE - Belgio 53
NG - Nigeria 42
GR - Grecia 33
SN - Senegal 33
BR - Brasile 30
PL - Polonia 29
NL - Olanda 21
AU - Australia 18
IR - Iran 14
JP - Giappone 13
CZ - Repubblica Ceca 12
RO - Romania 11
ES - Italia 10
IE - Irlanda 10
KR - Corea 10
BJ - Benin 9
MX - Messico 8
DK - Danimarca 7
IL - Israele 6
NZ - Nuova Zelanda 5
PH - Filippine 5
EG - Egitto 4
HU - Ungheria 4
LT - Lituania 4
ID - Indonesia 3
MY - Malesia 3
RS - Serbia 3
SA - Arabia Saudita 3
CO - Colombia 2
EC - Ecuador 2
EU - Europa 2
HR - Croazia 2
LU - Lussemburgo 2
NO - Norvegia 2
PK - Pakistan 2
PT - Portogallo 2
TW - Taiwan 2
A1 - Anonimo 1
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CL - Cile 1
CU - Cuba 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IQ - Iraq 1
JO - Giordania 1
LB - Libano 1
LK - Sri Lanka 1
MA - Marocco 1
MK - Macedonia 1
NP - Nepal 1
QA - Qatar 1
TH - Thailandia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 28.015
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.819
Ann Arbor 1.960
Houston 1.889
Fairfield 1.826
Chandler 1.176
Santa Clara 1.020
Ashburn 968
Seattle 857
Wilmington 711
Cambridge 686
Sofia 638
Shanghai 552
Milan 525
Serra 478
Beijing 397
New York 382
Singapore 368
Ottawa 350
Boardman 346
Jacksonville 293
Princeton 274
Izmir 270
Lawrence 257
Medford 220
Nanjing 199
Des Moines 163
Abidjan 160
Dong Ket 159
Dearborn 153
Istanbul 114
Nanchang 91
San Diego 88
Hong Kong 84
Falls Church 83
Bern 80
Washington 77
Boulder 75
Florence 73
Vienna 73
Rome 72
Pisa 70
Ogden 68
London 67
Frankfurt am Main 58
Redwood City 58
Jüchen 51
Brussels 50
Bremen 49
Düsseldorf 49
Kunming 44
Lagos 42
Hebei 40
Los Angeles 39
Shenyang 37
Changsha 35
Fuzhou 35
Norwalk 35
Dakar 33
Marseille 32
Rho 31
Nürnberg 29
Pune 29
Jiaxing 28
Seacroft 28
Warsaw 28
Helsinki 27
Tianjin 23
Guangzhou 22
Lucca 22
Hangzhou 21
Hefei 21
Quanzhou 21
Auburn Hills 19
Dallas 18
Lancaster 17
Cascina 16
Munich 16
Phoenix 16
Vicopisano 16
Livorno 14
Orange 13
Toronto 12
Wuhan 12
Indiana 11
Jinan 10
Simi Valley 10
Tappahannock 10
Cotonou 9
Lanzhou 9
Zhengzhou 9
Amsterdam 8
Chicago 8
Chongqing 8
Hyderabad 8
Dülmen 7
Genoa 7
Kilburn 7
Melbourne 7
Ningbo 7
San Francisco 7
Totale 22.539
Salva come PNG Salva come JPEG
Nome #
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 328
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity 312
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma 221
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 203
A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer 201
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 199
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 197
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 196
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. 183
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 182
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia 182
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 175
Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? 174
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 172
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 171
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 167
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 165
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients 165
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 162
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 161
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 160
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 160
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 159
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation 157
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity 154
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 153
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 153
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 153
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 152
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 150
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice 149
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine 149
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 148
Tumor Dormancy, Angiogenesis and Metronomic Chemotherapy 147
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 144
Chronic administration of suramin induces neurotoxicity in rats 144
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 143
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 139
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. 139
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 139
The pharmacological bases of the antiangiogenic activity of paclitaxel 137
John Hunter and the origin of the term “angiogenesis”. 136
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy 135
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 135
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 135
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 135
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 134
Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis 133
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 133
ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. 133
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. 132
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 132
Scholars and scientists in the history of the lymphatic system 132
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 132
Appropriateness of repetitive therapeutic drug monitoring and laboratory turn around time 132
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 131
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 130
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 130
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 130
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 130
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 129
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 128
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation 127
null 127
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 126
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 126
Pharmacogenetics of Antiangiogenic Therapy 125
Looking for the Word “Angiogenesis” in the History of Health Sciences: From Ancient Times to the First Decades of the Twentieth Century 125
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 123
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 123
Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo 123
5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients 122
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer 122
Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? 122
Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules 122
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 121
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 121
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 120
Microvessel density in human normal and neoplastic parathyroids 119
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 119
TREATMENT OF CANINE LYMPHOMA AS A MODEL FOR HUMANS 119
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections 119
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 118
The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization 118
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice 118
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 118
Biologic basis of ovarian metastasis of colorectal cancer 117
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations 116
The possible role of chemotherapy in antiangiogenic drug resistance 116
Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia 116
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines 116
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 115
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 115
The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment 114
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 114
null 114
CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation 114
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 114
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies 113
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 113
Totale 14.352
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.291 0 0 0 0 0 0 576 413 544 317 338 103
2020/20212.407 218 238 212 92 225 123 86 240 230 242 125 376
2021/20222.884 50 209 79 132 494 489 91 128 128 115 158 811
2022/20233.577 463 445 254 331 447 458 13 269 636 21 196 44
2023/20242.569 302 289 318 171 350 466 77 108 65 47 104 272
2024/20252.823 45 335 80 452 746 866 299 0 0 0 0 0
Totale 28.591